Trial Profile
Prospective, Placebo-controlled, Double-blind, Randomized Clinical Study to Assess the Safety and Efficacy of Topical Treatment of AR/101 Compared With for up to 28 Days, in Accelerating Granulation Tissue Formation in Chronic Wound Patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs AR 101-Arava (Primary)
- Indications Wounds
- Focus Therapeutic Use
- Sponsors Arava Bio Tech
- 21 Jul 2016 New trial record